SPTX · Seaport Therapeutics, Inc.
$18.42
-0.53 (-2.80%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— cleared Jun 8, 2026
The latest filing states the doubt was alleviated.
“the Company has evaluated whether there are conditions and events that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company believes that its existing cash, cash equivalents and investments of $212.6 million as of March 31, 2026, together with the additional proceeds received from the IPO, will be sufficient to allow the Company to fund operations at least twelve months from the date that of these condensed consolidated financial statements are issued.”View the 10-Q filed Jun 8, 2026
Market Cap
$1.15B
Shares
53.53M
Volume · Oct 2
258.7K
Avg daily vol (3M)
179.97K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$18.42
Open$19.16
Day$17.85–19.16
Available close range$15.25–27.84
Avg vol 30d249K
Short int3.1M · 5.9% float · 20.7d
Short vol91%
Last earningsAug 3, 2026
DataMay 2026–Oct 2026
Filing10-Q · Aug 3
The closing range uses available history since May 1, 2026; less than a full year is stored.
Up next
filed Aug 3, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$273.31M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,395.1%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
5.9%
Latest settlement · 20.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Limited
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−18%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
25%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+54 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.88% of float · ▼ -0.1% MoM · 20.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
54 holders — 13F breadth
Squeeze score
69
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
10.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−18%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
25%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+54 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.88% of float · ▼ -0.1% MoM · 20.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
54 holders — 13F breadth
Price context
position in its available closing range
Range low $15
Now $18 · 25%
Range high $28
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SPTX
this stock
Seaport Therapeutics, Inc.
|
$1.15B | — | — | — | 5.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SPTX | -14.4% | -24.2% | — | -8.7% | — |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -14.2% | -23.7% | — | -9.6% | — |